MitoRx Therapeutics Competitors and Similar CompaniesClear all
MitoRx Therapeutics's competitors and similar companies include Mesoblast, ImmusanT, Human Stem Cells Institute and Unicycive Therapeutics.
 MitoRx Therapeutics MitoRx Therapeutics is a biotechnology company that specializes in degenerative disease treatment solutions. |  Mesoblast Mesoblast specializes in the development of biologic products for the broad field of regenerative medicine. |  ImmusanT ImmusanT is a clinical development-stage biotechnology company focused on an innovative disease-modifying approach to induce immune tolerance in autoimmune diseases. |  Human Stem Cells Institute Human Stem Cells Institute is a biomedical technologies and healthcare solutions provider. |  Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company that develops treatment for kidney diseases with significant unmet medical needs. | |
Founding Date | Founding Date 2021 | Founding Date 2004 | Founding Date 2010 | Founding Date 2003 | Founding Date 2016 |
Type | Type Private | Type Public | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Oxford, GB HQ Exeter, GB | Locations Melbourne, AU HQ Singapore, SG New York, US | Locations Cambridge, US HQ | Locations Moscow, RU HQ | Locations Los Altos, US HQ |
Employees | Employees 16 | Employees 73 | Employees 2 | Employees N/A | Employees 1 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.2 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 45.5 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $17.2m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) ₽1.7b (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $1.2m (FY, 2025) | Cost of goods N/A | Cost of goods ₽330.8m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $16.1m (FY, 2025) | Gross profit N/A | Gross profit ₽1.4b (FY, 2025) | Gross profit N/A |
Net income | Net income N/A | Net income ($102.1m) (FY, 2025) | Net income N/A | Net income ₽107.7m (FY, 2025) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised $ 4m | Total funding raised $ 56.2m | Total funding raised $ 72.8m | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Mesoblast
HQ
Melbourne, AU
Employees
73
Mesoblast specializes in the development of biologic products for the broad field of regenerative medicine.
View companyImmusanT
HQ
Cambridge, US
Employees
2
ImmusanT is a clinical development-stage biotechnology company focused on an innovative disease-modifying approach to induce immune tolerance in autoimmune diseases.
View companyHuman Stem Cells Institute
HQ
Moscow, RU
Human Stem Cells Institute is a biomedical technologies and healthcare solutions provider.
View companyUnicycive Therapeutics
HQ
Los Altos, US
Employees
1
Unicycive Therapeutics is a biotechnology company that develops treatment for kidney diseases with significant unmet medical needs.
View company